Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00568490

Enrollment

200

Registered

2007-12-06

Start date

1998-09-01

Completion date

2027-06-30

Last updated

2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer, Head and Neck Cancers, Lip Cancer, Lip Neoplasms, Lung Cancer

Brief summary

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Detailed description

The endpoints of the study are 1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance. 2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.

Interventions

PROCEDURETumor biopsy

For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen

PROCEDUREPhlebotomy

Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck. * Able to sign a Stanford IRB approved consent form

Exclusion criteria

* Refuse or unable to sign an IRB approved consent form. * Refuse to be contacted in the future for follow up.

Design outcomes

Primary

Measure	Time frame
Identification of Secreted Markers for Tumor Hypoxia through tissue collection	before therapy, weekly during therapy

Countries

United States

Contacts

CONTACTEyiwunmi Laseinde

Rad-onc-ccto@lists.stanford.edu

PRINCIPAL_INVESTIGATORQuynh-Thu Le

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026